All In MedTech

Device Trial Radar · NCT02365454

NEXUS™ Aortic Arch Stent Graft System First In Man Study

Feasibility Clinical Study to Evaluate the Safety and Performance of the NEXUS™ Aortic Arch Stent Graft System

Last checked: Nov 20, 2026Latest source record: Sep 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

18

Actual

Start

Aug 2014

Primary completion

Nov 2018

Study completion Jun 2023

Sponsor

Lead sponsor
Endospan Ltd.Not on our public-company list
Sponsor type
Industry
First posted
Feb 19, 2015

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 95 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A multicenter, prospective, open-label, non-randomized, interventional clinical study, sponsored by Endospan Ltd. Patients will be followed-up for five years.

Conditions

  • Thoracic Aortic Arch Disease
  • Thoracic Aortic Aneurysm

Interventions

  • Stent Graft Placement (Nexus)Device

    The Nexus stent graft is introduced through a groin to the diseased location at the Aortic Arch. Depending on the patients anatomy and other medical considerations the physician may decide that blood flow to the sub-clavian artery and possibly also to the left carotid artery is required to be maintained via "surgical bypass grafting", either immediately, or a few days, before the implantation. In addition to the incision for introducing the investigational stent graft, two smaller access sites are required, one at the groin on the opposite side and on into the Right Arm to the Brachial Artery. This endovascular procedure will likely require full anesthesia. The entire procedure is assisted by an angiography imaging system.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety: Device related mortality at 30 days post implantationTime frame: 30 days

Locations

4 sites in 3 countries. Site status is shown where the registry gives one.

  • Faculty Hospital Hradec Kralove

    Hradec Králové, Czechia

  • San Filippo Neri Hospital

    Rome, Italy

  • Zurich University Hospital

    Zurich, Switzerland

1 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.